{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:12:38Z","timestamp":1771305158866,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T00:00:00Z","timestamp":1600560000000},"content-version":"vor","delay-in-days":263,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.4158\/accr-2019-0234","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T14:18:00Z","timestamp":1578061080000},"page":"e40-e45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma"],"prefix":"10.1016","volume":"6","author":[{"given":"Sara","family":"Bedrose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie G.","family":"Turin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor R.","family":"Lavis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali N.","family":"Thosani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/ACCR-2019-0234_bb0010","article-title":"Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy","volume":"10","author":"Sahni","year":"2018","journal-title":"Cureus"},{"key":"10.4158\/ACCR-2019-0234_bb0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"key":"10.4158\/ACCR-2019-0234_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.4158\/ACCR-2019-0234_bb0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","article-title":"Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy","volume":"66","author":"Okahata","year":"2019","journal-title":"Endocr J"},{"key":"10.4158\/ACCR-2019-0234_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.4158\/ACCR-2019-0234_bb0035","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/ACCR-2019-0234_bb0040","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","author":"Haddad","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.4158\/ACCR-2019-0234_bb0045","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"10.4158\/ACCR-2019-0234_bb0050","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4158\/ACCR-2019-0234_bb0055","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3389\/fimmu.2018.02142","article-title":"Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy","volume":"9","author":"Corvillo","year":"2018","journal-title":"Front Immunol"},{"key":"10.4158\/ACCR-2019-0234_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02786513","article-title":"Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation an autoimmune phenomenon","volume":"18","author":"Levy","year":"1998","journal-title":"Immunol Res"},{"key":"10.4158\/ACCR-2019-0234_bb0065","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/archderm.1987.01660360090018","article-title":"Lipoatrophic panniculitis: a possible autoimmune inflammatory disease of fat. Report of three cases","volume":"123","author":"Billings","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.4158\/ACCR-2019-0234_bb0070","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/ACCR-2019-0234_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Araujo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/ACCR-2019-0234_bb0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00415-006-0898-0","article-title":"Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis","volume":"253","author":"Beiske","year":"2006","journal-title":"J Neurol"},{"key":"10.4158\/ACCR-2019-0234_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/373524","article-title":"The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients","volume":"2009","author":"Sutinen","year":"2009","journal-title":"PPAR Res"},{"key":"10.4158\/ACCR-2019-0234_bb0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"10.4158\/ACCR-2019-0234_bb0095","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520300651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060520300651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:31:24Z","timestamp":1762497084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060520300651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2376060520300651"],"URL":"https:\/\/doi.org\/10.4158\/accr-2019-0234","relation":{},"ISSN":["2376-0605"],"issn-type":[{"value":"2376-0605","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/ACCR-2019-0234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}